"$30 million acquisition facility (finalising terms) out of a total finance facility of $36 million - $9 million drawn at IPO with balance being used to fund future acquisitions"
They suggest that each new practice can be purchased for under $1.5m and will be earnings accretive.
"Organic revenue growth on track for 3.5% growth in FY18"
"$3.7 million identified through increased chair utilisation and patient increases" off a net revenue base of $35m
The growth rate will be easily proved or disproved as they project FY18 which has 3 months to run. I would suggest though with a quarter to go their numbers would be fairly discernible.
SIL Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held